DGAP-News: Neovacs S.A.: NEOVACS GRANTED 1 MILLION EURO IN RESEARCH TAX CREDIT


DGAP-News: Neovacs S.A. / Key word(s): Miscellaneous
Neovacs S.A.: NEOVACS GRANTED 1 MILLION EURO IN RESEARCH TAX CREDIT

24.11.2014 / 18:03

---------------------------------------------------------------------

NEOVACS GRANTED 1 MILLION EURO IN RESEARCH TAX CREDIT

Paris, November 24, 2014 - NEOVACS (Alternext Paris : ALNEV), a leader in
active immunotherapies for the treatment of autoimmune diseases, today
announced that it has received EUR1 million in research tax credit for R&D
expenses incurred in 2013, in line with Company expectations.

"The funds that we received today strengthen our financial position. They
come in addition to the financing options that we have arranged, and
increase our cash runway for 2015", commented Miguel Sieler, Neovacs Chief
Executive Officer. "Consistent with the Company's development plan, we will
obtain and release the results of a Phase IIb study of TNF-Kinoid in
Rheumatoid Arthritis before the end of the year. We also expect to launch a
Phase IIb clinical trial of IFNα-Kinoid in Lupus in 2015".

The funds received today will be used to fund the clinical and pre-clinical
development of Neovacs' therapeutic vaccines portfolio.

About Neovacs

Neovacs is a biotechnology company focused on an active immunotherapy
technology platform (Kinoids) with applications in autoimmune and/or
inflammatory diseases. On the basis of the company's proprietary technology
for inducing a polyclonal immune response (covered by five patent families
that run until at least 2026) Neovacs is focusing its development efforts
on two active immunotherapies: TNF-Kinoid is being developed for the
treatment of TNF-mediated autoimmune diseases such as rheumatoid arthritis
and Crohn's disease, whereas IFNα-Kinoid is being developed for the
indication of lupus. The goal of the Kinoid approach is to enable patients
to have access to safe treatments with efficacy that is sustained in these
life-long diseases.

For more information on Neovacs, visit www.neovacs.fr

Contacts 

NEOVACS       
Nathalie Trépo        
+33 (0)1 53 10 93 00      
ntrepo@neovacs.com      

Press - Financial Communications- Publicis
Stéphanie Tabouis
+33 (0) 1 44 82 46 35
stéphanie.tabouis@consultants.publicis.fr



---------------------------------------------------------------------

24.11.2014 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------


Language:    English                                             
Company:     Neovacs S.A.                                        
             3-5, Impasse Reille                                 
             75014 Paris                                         
             France                                              
Phone:       +33 (0)1 53 10 93 00                                
Fax:         +33 (0)1 53 10 93 03                                
E-mail:      www.neovacs.fr                                      
Internet:    info@neovacs.fr                                     
ISIN:        FR0004032746                                        
WKN:         A1CVKR                                              
Listed:      Freiverkehr in Stuttgart; Frankfurt in Open Market  
 
 
End of News    DGAP News-Service  
---------------------------------------------------------------------  
299031 24.11.2014